

CS/NSE/UFR/2012-13
November 14, 2012

TO
THE MANAGER
LISTING DEPARTMENT
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
EXCHANGE PLAZA, BANDRA KURLA COMPLEX
BANDRA (E), MUMBAI - 400 051

Dear Sir/Madam,

Stock Code - SUVEN-EQ

Sub: Notification of Un-audited Financial Results for the quarter ended
30/09/2012 - Clause 41

.....

With reference to the above subject, we are forwarding here with Un-audited Financial Results of our Company for three/six months ended 30th September, 2012 in the prescribed proforma, as required under Clause-41 of the listing agreement as amended. The Board of Directors of our company has taken on record the enclosed Un-audited Financial Results for the 2nd Quarter in its meeting held on 14th November, 2012.

Please find enclosed Press release of our company. We request you to take these Documents on your Records

Thanking You,

Yours faithfully,
For SUVEN LIFE SCIENCES LIMITED


K HANUMANTHA RAO
Company Secretary

Suven Life Sciences Limited

Regd. Office: Avenue Chambers, Road # 3, Avenue 7, Bandra Hills, Mumbai 400 074, INDIA

TEL: 91-40-2294 1142/ 3311, 3232, 1695, 66; Fax: 91-40-1004 1157

info@suven.com

www.suven.com

Going beyond Commitment.



SUVEN LIFE SCIENCES LTD

Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034
UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30 th SEPT 2012

PART - I		(in Lacs), except share data			Rs. in Lacs	
Sl. No.	PARTICULARS	Quarter Ended			Year to date figures	
		30/9/2012	30/6/2012	30/09/2011	30/09/2012	30/09/2011
		Unaudited	Un-audited	Unaudited	Unaudited	Audited
1	Income from operations					
	(a) Net sales/income from operations (Net of excise duty)	5,025.90	7,052.72	4,804.38	12,078.62	9,267.66
	(b) Other operating income	-	-	-	-	-
	Total income from operations (net)	5,025.90	7,052.72	4,804.38	12,078.62	9,267.66
2	Expenses					
	a) Cost of materials consumed	1,683.66	2,144.63	1,678.55	3,828.29	3,532.66
	b) Purchases of stock-in-trade	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(301.91)	330.84	(92.73)	28.93	(103.35)
	d) Employee benefits expense	562.82	651.73	594.21	1,214.55	1,065.68
	e) Depreciation and amortisation expense	170.05	183.23	140.02	353.28	278.74
	f) Other expenses - Manufacturing Exps	893.71	848.55	585.70	1,742.26	1,139.77
	- Selling Exps	83.58	100.21	83.00	183.79	131.41
	- Administrative Exps	596.52	517.42	298.03	1,113.94	578.96
	- R & D Exps	682.80	874.68	877.31	1,557.48	1,625.13
	- Provision for MTM on Forward Contracts	(314.27)	250.96	541.86	(63.31)	541.86
	Total expenses	4,056.96	5,902.25	4,705.95	9,959.21	8,790.86
3	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	968.94	1,150.47	98.43	2,119.41	476.80
4	Other income	(39.26)	52.47	162.28	13.21	182.56
5	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 ± 4)	929.68	1,202.94	260.71	2,132.62	659.36
6	Finance costs	289.75	321.92	192.97	611.67	356.55
7	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 ± 6)	639.93	881.02	67.74	1,520.95	302.81
8	Exceptional items	-	-	-	-	-
9	Profit/Loss from Ordinary Activities before tax (7 ± 8)	639.93	881.02	67.74	1,520.95	302.81
10	Tax Expenses	(8.96)	84.68	(188.38)	75.72	(289.40)
11	Net Profit/ (Loss) from Ordinary Activities after tax (9 ± 10)	648.89	796.34	256.12	1,445.23	592.21
12	Extraordinary Items (net of tax expense Lakhs)	-	-	-	-	-
13	Net Profit (+)/Loss(-) for the period (11 ± 12)	648.89	796.34	256.12	1,445.23	592.21
14	Share of profit / (loss) of associates*	-	-	-	-	-
15	Minority interest *	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 ± 14 ± 15) *	-	-	-	-	-
17	Paid-up equity share capital (Face Value of the Share shall be indicated)	1,167.32	1,167.32	1,167.32	1,167.32	1,167.32
		Rs. 1.00	Rs. 1.00	Rs. 1.00	Rs. 1.00	Rs. 1.00
18	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	11,584.83
19.i	Earning Per Share (EPS) (before extraordinary items) (of Rs.1/- each) (not annualised):					
	a) Basic	0.56	0.68	0.22	1.24	0.51
	b) Diluted	0.56	0.68	0.22	1.24	0.51
19.ii	Earning Per Share (EPS) (after extraordinary items) (of Rs.1/- each) (not annualised):					
	a) Basic	0.56	0.68	0.22	1.24	0.51
	b) Diluted	0.56	0.68	0.22	1.24	1.23

PART - II

	30/9/2012	30/6/2012	30/09/2011	30/09/2012	30/09/2011	31/3/2012
A PARTICULARS OF SHAREHOLDING	Unaudited	Un-audited	Unaudited	Unaudited	Unaudited	Audited
1 Public share holdings						
- Number of shares	42,679,160	42,679,160	42,679,160	42,679,160	42,679,160	42,679,160
- Percentage of Share holding	36.56%	36.56%	36.56%	36.56%	36.56%	36.56%
2 Promoters and promoter group Shareholding**						
a) Pledged / Encumbered	NIL	NIL	NIL	NIL	NIL	NIL
- Number of shares						
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of the total share capital of the company)	NIL	NIL	NIL	NIL	NIL	NIL
b) Non-Encumbered	74,052,828	74,052,828	74,052,828	74,052,828	74,052,828	74,052,828
- Number of shares						
- Percentage of Shares (as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	63.44%	63.44%	63.44%	63.44%	63.44%	63.44%
Particulars	3 months ended (30/09/2012)					
B INVESTOR COMPLAINTS						
Pending at the beginning of the quarter	0					
Received during the quarter	20					
Disposed of during the quarter	20					
Remaining unresolved at the end of the quarter	0					

SEGMENT WISE REVENUE, RESULTS AND CAPITAL EMPLOYED							Rs. In Lacs
PARTICULARS	Quarter Ended			Year to date figures		Year Ended	
	30/9/2012	30/6/2012	30/09/2011	30/09/2012	30/09/2011		
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1 SEGMENT REVENUE :-							
a) Manufacturing (CRAMS)	4,359.17	6,514.95	4,358.64	10,874.12	8,674.26	19,168.87	
b) Services (DDSS)	666.73	537.77	454.23	1,204.50	612.45	1,251.91	
c) Research & Development	-	-	-	-	-	-	
Net Sales from Operations	5,025.90	7,052.72	4,812.87	12,078.62	9,286.71	20,420.78	
2 SEGMENT RESULTS :-							
Profit/(Loss) before tax and interest:							
a) Manufacturing (CRAMS)	1,417.44	2,494.37	1,512.59	3,911.81	2,839.90	6,507.91	
b) Services (DDSS)	406.29	231.20	279.78	637.49	348.33	531.83	
c) Research & Development	(682.80)	(874.68)	(877.31)	(1,557.48)	(1,625.13)	(3,304.91)	
TOTAL	1,140.93	1,850.89	915.06	2,991.82	1,563.10	3,734.83	
Less: i) Interest	261.41	298.14	192.97	559.55	356.55	888.50	
ii) Other Un-allocable exps net off un-allocable Income	239.59	671.73	654.35	911.32	903.74	1,932.15	
Total Profit Before Tax	639.93	881.02	67.74	1,520.95	302.81	914.18	
3 CAPITAL EMPLOYED							
(Segment Assets - Segment Liabilities)							
a) Manufacturing (CRAMS)	11,544.66	11,483.10	12,566.39	11,544.66	12,566.39	10,704.10	
b) Services (DDSS)	3,137.56	3,131.68	381.73	3,137.56	381.73	3,298.34	
c) Research & Development	2,513.05	2,525.28	3,438.29	2,513.05	3,438.29	2,228.26	
d) Net assets which are not segmented and used commonly	4,613.35	1,564.05	3,569.93	4,613.35	3,569.93	2,023.90	
TOTAL	21,808.62	18,704.11	19,956.34	21,808.62	19,956.34	18,254.60	

- Notes:
- 1) The above un-audited results were approved and taken on record at the Board of Directors meeting held on 14th Nov 12
 - 2) Previous years figures have been regrouped / reclassified whenever necessary.
 - 3) The limited review has been completed by the Statutory Auditors.
 - 4) Provision for MTM Losses/gains pertaining to Forward Contracts entered for covering the future receivables in USD.
 - 5) Suven Nishta Pharma pvt ltd, the 100% subsidiary, has been merged wef 1st Jan 2012 and accordingly the results have been prepared. Hence the current year's figures are not comparable with the previous year figures.

Place : Hyderabad
Date : 14th Nov/2012

For SUVEN LIFE SCIENCES LTD


VENKAT JASTI
Chairman & CEO

We Deliver



SUVEN LIFE SCIENCES LTD


Regd. Off: Serene Chambers, Road No.5, Banjara Hills, Hyderabad - 500 034

Standalone Statement of Assets & Liabilities as per Clause 41(V)(h) as per Listing agreement

(Rs. in lakhs)

	Particulars	Half year Ended	
		9/30/2012	3/31/2012
A	EQUITY AND LIABILITIES		
1	Shareholder's funds:		
	(a) Share Capital	1,167.32	1,167.32
	(b) Reserves and Surplus	13,030.05	11,584.83
	Sub-total - Shareholders' funds	14,197.37	12,752.15
2	Non-current liabilities		
	(a) Long-term borrowings	7,637.59	5,502.45
	(d) Long-term provisions	249.21	179.21
	Sub-total - Non-current liabilities	7,886.80	5,681.66
3	Current liabilities		
	(a) Short-term borrowings	3,305.91	2,285.40
	(b) Trade payables	2,177.50	2,454.11
	(c) Other current liabilities	3,621.10	4,077.76
	(d) Short-term provisions	646.99	1,247.64
	Sub-total - Current liabilities	9,751.50	10,064.91
	TOTAL - EQUITY AND LIABILITIES	31,835.67	28,498.72
B	ASSETS		
1	Non-current assets		
	(a) Fixed assets	16,257.36	15,979.99
	(b) Non-current investments	5.10	5.10
	(c) Deferred tax assets (net)	1,677.07	1,760.96
	(d) Long-term loans and advances	590.76	272.82
	Sub-total - Non-current assets	18,530.29	18,018.87
2	Current assets		
	(a) Current investments	2,656.67	447.33
	(b) Inventories	4,269.41	4,650.17
	(c) Trade receivables	2,955.52	2,523.93
	(d) Cash and cash equivalents	629.45	316.87
	(e) Short-term loans and advances	2,783.71	2,528.87
	(f) Other current assets	10.62	12.68
	Sub-total - Current assets	13,305.38	10,479.85
	TOTAL - ASSETS	31,835.67	28,498.72

For Suven Life Sciences Ltd



Venkat Jasti
Chairman & CEO

SUVEN Life Sciences



News Release

Suven's PAT up by 153% for the quarter ended 30th September' 2012.

HYDERABAD, INDIA (14 Nov 2012) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its un-audited financial results for the quarter ended 30th Sept 2012. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th Nov, 2012 at Hyderabad.

Financial Highlights for the 2nd Quarter ended September 2012:

Growth in revenue	Rs 503 mil vs. Rs 480 mil	- Up by 4.61%
Growth in PAT	Rs 64 mil vs. Rs 25 mil	- Up by 153%
Growth in EBITDA	Rs 110 mil vs. Rs 40 mil	- Up by 174%

Financial Highlights for the Half year ended September 2012:

Growth in revenue	Rs 1208 mil vs. Rs 927 mil	- Up by 30%
Growth in PAT	Rs 145 mil vs. Rs 59 mil	- Up by 144 %
Growth in EBITDA	Rs 249 mil vs. Rs 94 mil	- Up by 165 %

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 156 mil (13% on revenue) for the half year ended Sept' 2012.

During the quarter the major qualitative achievement include Suven getting Pharmexcil's "Platinum Patent Award" for securing the most number of product and process patents under overall category, fourth year in a row. Suven has a patent profile of 18 inventions, 541 product patents and 36 process patents. The product profile has 13 molecules with one molecule having completed phase 1 study, is in the process of moving into phase 2a, proof of concept study.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;